Nexus Infrastructure – ‘profits in line’ (are they?), ‘order book provides good visibility of earnings’ (does it?)…
Hello Share Sloggers. Fancy investing in another AIM-listed company that is pioneering new medical treatments? Yes, I thought you might be a bit wary. But some of these ventures will come up roses, eventually.
Hello, Share Choosers. As we've often said on this glittering website, investing in small drugs companies is fraught with peril. Cures and remedies take ages to develop, and then you have to steer them through a punishing licence minefield. I’m a great believer, though, in this kind of punt, as the world becomes older and less healthy. And investment in the right pharma could reap big rewards for shareholders, but mainly the sick among us. Today’s suggestion seems a more promising pocket pharma than most.
On the face of it you would think that the daily chart of ImmuPharma represents a classic breakdown over recent months, one which would be a falling knife to catch for all but the most brave of bargain hunters.
As yet another reminder that technical analysts are not always momentum followers we have the present situation at Immupharma. What can be seen here is that since July last year there has been a descending price channel which has effectively halved the share price from the October peak above 70p. However, we do have near-term positive charting triggers.
Search ShareProphets |
Recent Comments |